ALX-0171

BIOLOGICAL4 trials

Sponsors

Ablynx, a Sanofi company

Conditions

HealthyRSV InfectionRespiratory Syncytial Virus Infection

Phase 1

ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers

CompletedNCT01483911

Ablynx, a Sanofi companyRSV Infection

Start: 2011-11-30End: 2012-05-31Updated: 2018-07-13

ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers

CompletedNCT01875926

Ablynx, a Sanofi companyHealthy, RSV Infection

Start: 2013-05-31End: 2013-10-31Updated: 2018-07-13

ALX-0171 Safety Study in Adults With Hyperresponsive Airways

CompletedNCT01909843

Ablynx, a Sanofi companyRespiratory Syncytial Virus Infection

Start: 2013-07-31End: 2013-12-31Updated: 2018-07-13

A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171

CompletedNCT02309320

Ablynx, a Sanofi companyRespiratory Syncytial Virus Infection

Start: 2014-12-31End: 2016-02-29Updated: 2019-01-10